Chemical & Engineering News The National Institutes of Health’s flagship long COVID initiative, RECOVER—short for Researching COVID to Enhance Recovery—has after a year of deliberation selected several drug candidates to test as treatments for the condition.
Over the course of a 2-day workshop in Bethesda, Maryland, this week, RECOVER representatives detailed plans to launch clinical trials for several interventions. Those include glucagon-like peptide-1 (GLP-1) drugs, like tirzepatide; stellate ganglion block, a procedure involving the injection of anesthetic into the stellate ganglion nerves to improve circulation; and low-dose naltrexone, a version of a drug for opioid and alcohol use disorders that’s often prescribed off-label for chronic pain.
RECOVER will also allocate additional funding for an ongoing trial of baricitinib, a Janus kinase (JAK) inhibitor made by Eli Lilly and Company that’s approved to treat alopecia and rheumatoid arthritis.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.